Efficacy and safety of risankizumab in moderate-to-severe Crohn's disease: a systematic review and meta-analysis - PubMed

4 hours ago

Risankizumab is significantly more effective than placebo or active comparator in achieving clinical remission in Crohn's disease during both induction (RR 1.85) and maintenance phases (RR 1.40).
The treatment shows robust endoscopic outcomes, with significant rates of endoscopic remission (RR 2.81) and response (RR 4.17) post-induction, and increases mucosal healing (RR 3.40).
Risankizumab reduces the risk of Crohn's disease-related hospitalizations by 78% (RR 0.22) and improves fecal calprotectin levels, but shows no significant benefit for high-sensitivity C-reactive protein maintenance.
The meta-analysis included seven RCTs with a total of 4411 patients, using a random-effects model, and found treatment effects consistent across doses, though heterogeneity was noted in maintenance outcomes.
Overall, risankizumab is concluded to be an effective and safe option for inducing and maintaining remission in moderate-to-severe Crohn's disease, warranting further long-term studies and integration into clinical guidelines.

Hasty Briefsbeta